All News

RheumNow Podcast square

RheumNow Live is Coming to Town (3.11.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
myositis.jpg

Predicting Treatment Response in Inflammatory Muscle Disorders

d MedPage Today

Rheumatologists looking for clues to whether their patients with certain inflammatory myopathies will improve on immunosuppressive drugs may find them in a new study appearing in Arthritis Care & Research.

Read Article
CV,risk,MI,heart,cardiac

CV Risk Management in Rheumatic Disease Patients

d Jack Cush, MD

The European League against Rheumatism (EULAR) has developed recommendations for cardiovascular risk (CVR) management in rheumatic disease patients based on literature review and expert consensus.

Read Article
RheumNow Podcast square

Hand OA and Heroes in Rheumatology (2.11.2022)

d Jack Cush, MD

Interesting reports this week about dementia, who gets hand OA and a great list of women Heroes and Pillars of Rheumatology. Tune in as Dr. Jack Cush reviews the news and journal articles from this past week in RheumNow.com.

Read Article
vaccine.jpg

Hold Myophenolate or Not with COVID-19 Vaccination?

d Jack Cush, MD

While the American College of Rheumatology recommends holding mycophenolate (MMF) in rheumatic and musculoskeletal diseases patients (RMD) receiving COVID-19 vaccines, there is limited data on such an approach. A recent cohort study of RMD patients showed that holding MMF yielded higher antibody responses than continuing MMF.

Read Article
2021,year

2021 Rheumatology Year in Review

d Jack Cush, MD

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
covid coronavirus virus

New Onset Rheumatic Disorders with COVID-19 Infection

d Jack Cush, MD

The journal Cells has published a review of new rheumatic disorders following COVID-19 infection. Rheumatologists have infrequently noted such events and wondered what is the true incidence or range of possible manifestations.

Read Article
RheumNow Podcast square

Best of 2021: Jack of All Subspecialties

d Jack Cush, MD

It's great to be a rheumatologist, but boy, it's getting harder and harder. You have to be a jack of all trades. You have to be good at cardiovascular disease, osteoporosis, vaccination, inflammatory bowel disease - it just never ends. This and more, as Dr. Cush summarizes more than a dozen journal articles, news reports and questions + cases.

Read Article
Best of 2021: High Risk Cancer Profiling with Inflammatory Myositis A recent metanalysis of studies suggest you may be able to use certain clinical factors to stratify cancer risk in patients with idiopathic inflammatory myopathies (IIMs). https://t.co/v4F3jmfnNK https://t.co/1lflsgMZtE

Links:

Dr. John Cush RheumNow ( View Tweet)
Tofacitinib 1st JAK Inhibitor Approved for Ankylosing Spondylitis The FDA approved tofacitinib (Xeljanz, Xeljanz XR) for treating active ankylosing spondylitis in adults, Pfizer announced. https://t.co/NczbrBXBl7 https://t.co/l93OM86qaX

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Fiorentino on cancer risk stratification and screening in myositis. Come chat at noon in the Myositis Community Hub to learn more! #ACR21 #ACRAmbassador https://t.co/I0iQuPAuOl
Veena Katikineni VeenaRheumMD ( View Tweet)
Thanks Dr David Fiorentino for his talk on CA and myositis! ⬆️risk: - DM - >45-50yo - males - TIF1-gamma Ab (4.7RR of CA) - NXP2 - low CK - dysphagia ⬇️ risk: - synthetase Ab - raynaud - ILD - inflamm arth 🚨TIF1-gamma🚨 - ovarian CA (older, IgG2) #ACR21 #ACRAmbassador

Vaneet K Sandhu, MD (she/her/hers) vksandhumd ( View Tweet)

I remember, not that long ago, inclusion body myositis evoked resignation, for pts & clinicians. A bizarre condition where standard of care was counselling/mitigation Now there hope might be on the horizon Exciting to see the science & a feasible target #ACR21 ABSTL07 @RheumNow https://t.co/CYiAXIEA0Q
David Liew drdavidliew ( View Tweet)
Dr Preger report 9 novel aminoacyl tRNA synthetases in IIM patients. May these allow us to spare more patients biopsy? Abstr#0001 #ACR21 @RheumNow https://t.co/ikNXCEOeuj
Richard Conway RichardPAConway ( View Tweet)
Knowledge Bowl at #ACR21 ⭐️Approximately half of patients with IIM who develop pneumomediastinum have this subtype of dermatomyositis. ➡️Amyopathic (MDA5) dermatomyositis @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Dr Bass on the ICI M triad: Myositis, Myocarditis, Myasthenia--> Strongly a/w morbidity & mortality ~0.4% frequency, mortality 22% when myositis alone ~Overlap (+ myasthenia or myocarditis) more common w/ combination ICI, mortality 42% #ACR21 #ACRAmbassador https://t.co/g50tzAYhlS
Veena Katikineni VeenaRheumMD ( View Tweet)
If obvious dermatomyositis, you don’t need EMG for dx but may use for severity of involvement or if failing Rx or r/o steroid myopathy. For ?polymyositis ALWAYS do bx and often do EMG as broad differential #ACR21 @RheumNow https://t.co/L1xu3OuRYJ

Links:

Janet Pope Janetbirdope ( View Tweet)

@KatGilekMD @RichardPAConway @RheumNow @drhectorchinoy EMG/NCS can help uncover various neurological disorders including muscle dystrophies. Obviously it depends on center and expertise. Both MRI and EMG are useful and have different complementary utilities in Myositis. Many centers are not able to perform or interpret MRI reliably.

Rohit Aggarwal docrota ( View Tweet)

@NU_Rheum_MSK_US @RichardPAConway @drhectorchinoy @RheumNow Muscle ultrasound can be very useful but it is not ready for prime time currently to be used to do muscle biopsies. Perhaps in few years once we know how to target the muscle for biopsy.

Rohit Aggarwal docrota ( View Tweet)

Clinical (Peds Rheum) Pearl at #ACR21 by Dr. John Stone: ⭐️Dilated capillaries at the eyelid margin is the last cutaneous sign to resolve in inflammatory myositis! ⭐️Do not stop treatment until this sign is gone! #ACRBest @RheumNow https://t.co/5H3Q9mTN9x
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.